论文部分内容阅读
为比较乳糖化人生长激素（ｈＧＨ－Ｌ）和半乳糖基人生长激素（ｈＧＨ－Ｇａｌ）的肝靶向性，获得较理想的受体介导肝靶向促生长介素（ＳＯＭ），以提高人生长激素（ｈＧＨ）治疗侏儒症的效果。作者合成了ｈＧＨ－Ｌ和ｈＧＨ－Ｇａｌ，并以１３１Ｉ或１２５Ｉ标记ｈＧＨ－Ｌ、ｈＧＨ－Ｇａｌ和ｈＧＨ，进行小鼠体内分布实验和家兔显像实验对比研究，以及１３１Ｉ－ｈＧＨ－Ｌ、１３１Ｉ－ｈＧＨ－Ｇａｌ鸡显像和家兔体内竞争结合实验。结果：ｈＧＨ－Ｌ和ｈＧＨ－Ｇａｌ均具有明显的趋肝性，肝最大摄取率分别为６８．８３％～７４．６５％和６８．１６％～７４％，均约为ｈＧＨ的２倍，与肝脏的结合均具有受体介导结合特性。但ｈＧＨ－Ｌ的合成较ｈＧＨ－Ｇａｌ更为简单，而且反应条件温和，原料便宜得多。由此提示ｈＧＨ－Ｌ较ｈＧＨ－Ｇａｌ更可能成为受体介导肝靶向促ＳＯＭ分泌以治疗侏儒症的新药。
To compare the liver targeting of hGH-L and hGH-Gal, an ideal receptor-mediated liver-targeting somatomedin (SOM) Enhance the effect of human growth hormone (hGH) on dwarfism. The authors synthesized hGH-L and hGH-Gal and labeled 131I or 125I with hGH-L, hGH-Gal and hGH to compare the in vivo distribution in vivo with that in rabbits, as well as 131I-hGH-L, 131I -hGH-Gal chicken imaging and in vivo competition in rabbits. Results: Both hGH-L and hGH-Gal had a tendency to hepatopancreas. The maximal uptake rates of liver were 68.83% -74.65% and 68.16% -74% Liver binding all have receptor-mediated binding properties. However, the synthesis of hGH-L is more simpler than that of hGH-Gal, and the reaction conditions are mild and the raw materials are much cheaper. This suggests that hGH-L is more likely than hGH-Gal to be a new drug that mediates liver-targeted SOM secretion in order to treat dwarfism.